The evolving role of CETP inhibition: beyond HDL cholesterol

Lancet. 2015 Aug 1;386(9992):412-4. doi: 10.1016/S0140-6736(15)60608-0. Epub 2015 Jun 2.

Authors

Kausik K Ray¹, Antonio J Vallejo-Vaz²

Affiliations

¹ Department of Primary Care and Public Health, School of Public Health, Imperial College London, London W6 8RP, UK. Electronic address: k.ray@imperial.ac.uk.
² Cardiovascular Sciences, Cardiovascular and Cell Sciences Research Institute, St George's University of London, London, UK.

PMID: 26047976
DOI: 10.1016/S0140-6736(15)60608-0

No abstract available

Publication types

Comment

MeSH terms

Cholesterol Ester Transfer Proteins / antagonists & inhibitors*
Dyslipidemias / drug therapy*
Female
Fluorobenzenes / administration & dosage*
Heptanoic Acids / administration & dosage*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Male
Pyrimidines / administration & dosage*
Pyrroles / administration & dosage*
Quinolines / pharmacology*
Sulfonamides / administration & dosage*

Substances

Cholesterol Ester Transfer Proteins
Fluorobenzenes
Heptanoic Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pyrimidines
Pyrroles
Quinolines
Sulfonamides